Duvelisib (Copiktra): A Comprehensive Monograph on a Dual PI3K-δ/γ Inhibitor for Hematologic Malignancies

I. Executive Summary

Duvelisib, marketed under the brand name Copiktra, is a first-in-class, orally administered small molecule that functions as a dual inhibitor of the delta (δ) and gamma (γ) isoforms of phosphoinositide 3-kinase (PI3K).[1] It is approved for the treatment of adult patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received at least two prior lines of systemic therapy.[4] CLL and SLL are considered manifestations of the same disease, differing primarily in the location of the malignant cells, which are found predominantly in the bloodstream and bone marrow in CLL and in the lymph nodes in SLL.[2]

The regulatory approval of duvelisib for CLL/SLL was primarily based on the results of the pivotal Phase 3 DUO trial, a randomized study that compared duvelisib to the anti-CD20 monoclonal antibody ofatumumab.[6] In the indicated patient population of heavily pretreated individuals, duvelisib demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS), the study's primary endpoint.[8] This efficacy established duvelisib as a viable therapeutic option for a patient population with limited alternatives.

However, the clinical profile of duvelisib is characterized by a profound and complex duality. Its therapeutic efficacy is inextricably linked to a severe and challenging toxicity profile, which is a direct consequence of its dual PI3K inhibitory mechanism. This has led to a U.S. Food and Drug Administration (FDA) Black Box Warning, its most stringent caution, for fatal and/or serious toxicities, including infections, diarrhea or colitis, severe cutaneous reactions, and pneumonitis.[1] The management of these adverse events is a central aspect of duvelisib therapy and requires intensive patient monitoring and proactive intervention.

The regulatory and commercial landscape for duvelisib has been dynamic and challenging. The drug initially received accelerated approval from the FDA for the treatment of R/R follicular lymphoma (FL) based on the single-arm Phase 2 DYNAMO trial.[8] However, this indication was voluntarily withdrawn by the manufacturer in 2022, a business decision driven by the significant costs and logistical challenges of conducting the required confirmatory trials.[1] Furthermore, long-term follow-up data from the DUO trial, a post-marketing requirement, raised new safety concerns. In June 2022, the FDA issued a safety communication highlighting a possible increased risk of death with duvelisib compared to ofatumumab, alongside a higher rate of serious adverse events.[14] This finding has prompted a re-evaluation of the drug's overall benefit-risk profile and has further solidified its position as a late-line therapy.

In conclusion, duvelisib occupies a specific niche in the therapeutic armamentarium for hematologic malignancies. It is an effective agent for a heavily pretreated R/R CLL/SLL patient population, but its use is constrained by a significant risk of severe, immune-mediated toxicities. The decision to initiate duvelisib therapy requires a careful and individualized assessment, where the demonstrated benefits in disease control are meticulously weighed against the substantial and potentially life-threatening risks.

II. Scientific and Pharmacological Profile

This section details the fundamental scientific characteristics of duvelisib, including its chemical identity, mechanism of action, and pharmacokinetic properties. This foundational knowledge is essential for understanding its clinical efficacy, safety profile, and appropriate use in patient care.

A. Chemical Identity and Physicochemical Properties

Duvelisib is a small molecule drug designated with the DrugBank accession number DB11952 and the Chemical Abstracts Service (CAS) Registry Number 1201438-56-3.[1] During its development, it was also referred to by the investigational codes IPI-145 and INK-1197.[16]

The formal International Union of Pure and Applied Chemistry (IUPAC) name for the compound is 8-chloro-2-phenyl-3-isoquinolin-1-one.[16] Chemically, it is classified as an isoquinoline and purine derivative.[20] The molecular formula of the anhydrous compound is

C22​H17​ClN6​O.[1] The corresponding molar mass is 416.87 g·mol⁻¹.[1] The commercially available formulation is a hydrate, with the empirical formula

C22​H17​ClN6​O⋅H2​O and a molecular weight of 434.88 g/mol.[21]

Physically, duvelisib is a white-to-off-white crystalline solid.[21] Its solubility profile is characterized by solubility in organic solvents such as dimethyl sulfoxide (DMSO) and ethanol, while being practically insoluble in water.[21] This low aqueous solubility necessitates its formulation as an oral capsule for systemic delivery.

B. Pharmacodynamics: The Dual Inhibition of PI3K-δ and PI3K-γ

Duvelisib is classified pharmacologically as a kinase inhibitor, a class of targeted therapies that interfere with cell signaling pathways.[25] More specifically, it is a potent and reversible inhibitor of Phosphoinositide 3-kinase (PI3K).[1] It is distinguished as the first-in-class oral agent designed to dually inhibit the delta (

δ) and gamma (γ) isoforms of PI3K.[2]

The rationale for targeting these specific isoforms stems from their expression patterns. While the PI3K-α and PI3K-β isoforms are expressed ubiquitously throughout the body and are involved in fundamental processes like insulin signaling, the PI3K-δ and PI3K-γ isoforms are primarily restricted to leukocytes and other hematopoietic cells.[18] This selective expression provides a therapeutic window to target signaling pathways in hematologic malignancies while theoretically minimizing effects on other tissues.[28]

Impact on B-Cell Receptor (BCR) Signaling (PI3K-δ Inhibition)

The PI3K/AKT/mTOR pathway is a central signaling cascade that governs a wide array of cellular functions, including proliferation, survival, apoptosis, and metabolism.[1] In B-cell malignancies such as CLL, the B-cell receptor (BCR) signaling pathway is often constitutively active, leading to chronic and excessive activation of PI3K-

δ.[18] This aberrant signaling provides a constant pro-survival stimulus to the malignant cells, allowing them to evade apoptosis and proliferate uncontrollably.[18]

Duvelisib's primary anti-tumor effect is achieved through the potent inhibition of PI3K-δ. By blocking this enzyme, duvelisib interrupts the downstream signaling cascade, effectively cutting off the survival signals that the malignant B-cells depend upon.[6] This leads to a reduction in cell proliferation and the induction of apoptosis in the cancer cells.[19] Of note, preclinical data have shown that duvelisib can antagonize downstream signaling even in the presence of the BTK C481S mutation, a known resistance mechanism to the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib. This suggests a potential mechanism for activity in patients whose disease has become refractory to BTK inhibitor therapy.[18]

Modulation of the Tumor Microenvironment (PI3K-γ Inhibition)

In addition to its direct effects on malignant B-cells, duvelisib exerts a secondary, immunomodulatory effect through the inhibition of PI3K-γ. This isoform is critical for cytokine signaling, the pro-inflammatory response, and the trafficking and function of various immune cells that constitute the tumor microenvironment.[18] In many cancers, the tumor microenvironment is co-opted by the malignant cells to provide a supportive niche that fosters their growth and survival. Key components of this supportive environment include certain T-cell subsets and M2-polarized tumor-associated macrophages.[6]

By inhibiting PI3K-γ, duvelisib disrupts the signaling pathways that these supportive cells rely on. This action has been shown to reduce the recruitment and differentiation of pro-tumorigenic T-cells and macrophages within the tumor microenvironment.[6] This represents a distinct and complementary mechanism to the direct anti-proliferative effects of PI3K-

δ inhibition. The dual inhibition of both isoforms was shown in preclinical models to produce greater tumor growth inhibition than targeting the δ isoform alone, providing the foundational rationale for this broader mechanistic approach.[6]

The unique dual inhibitory mechanism of duvelisib, however, represents a double-edged sword. The theoretical advantage of a broader therapeutic attack, targeting both the malignant cell and its supportive niche, is counterbalanced by the profound biological consequences of inhibiting two key regulators of the immune system. The PI3K-δ and PI3K-γ isoforms are not only active in malignant cells but are also essential for the normal function of both the innate and adaptive immune systems.[18] Consequently, the simultaneous inhibition of both isoforms leads to a more extensive and profound state of immunosuppression than might be expected from a more selective agent. This widespread disruption of immune homeostasis is the direct mechanistic underpinning of the severe and characteristic pattern of immune-mediated toxicities observed in clinical practice. The high rates of serious infections, inflammatory colitis, pneumonitis, and severe cutaneous reactions are not disparate or unexpected side effects; rather, they are the predictable clinical manifestations of the drug's core pharmacodynamic activity. Therefore, the clinical experience with duvelisib is defined by an ongoing tension between the therapeutic benefit derived from its broad mechanism and the significant, life-threatening risks that arise from the same widespread immune modulation.

C. Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

The pharmacokinetic profile of duvelisib describes its movement into, through, and out of the body, which is critical for determining appropriate dosing and anticipating potential drug interactions.

Absorption: Following oral administration, duvelisib is rapidly absorbed, with the time to reach maximum plasma concentration (Tmax​) occurring within 1 to 2 hours.[1] The absolute bioavailability of a 25 mg dose is approximately 42%, indicating that a substantial portion of the oral dose reaches systemic circulation.[18]

Distribution: Duvelisib has a moderate volume of distribution, reported to be in the range of 26 to 102 L, suggesting distribution into tissues beyond the plasma volume.[18] It is highly bound to plasma proteins, with a binding percentage greater than 98% that is independent of serum concentration.[18] Duvelisib has also been identified as a substrate of the efflux transporters P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP), which can influence its distribution and absorption.[18]

Metabolism: The metabolism of duvelisib is almost entirely dependent on a single pathway: the cytochrome P450 3A4 (CYP3A4) enzyme system.[18] This reliance on a single, highly variable, and easily influenced enzyme is a central feature of its clinical pharmacology. The primary metabolic transformation is a mono-oxidation reaction that produces the metabolite IPI-656, which has no significant pharmacological activity.[23]

This singular metabolic pathway makes duvelisib's plasma concentration, and by extension its efficacy and toxicity, highly vulnerable to drug-drug interactions. CYP3A4 is responsible for the metabolism of over half of all clinically used drugs and its activity is notoriously affected by a wide range of common medications, supplements, and even foods. Strong inhibitors of CYP3A4 (e.g., ketoconazole, clarithromycin) can dramatically increase duvelisib concentrations, heightening the risk of severe toxicity. Conversely, strong inducers of CYP3A4 (e.g., rifampin, St. John's Wort) can significantly decrease duvelisib concentrations, potentially rendering the drug ineffective. This vulnerability is not a minor consideration but a critical risk that dictates clinical practice. The official prescribing information for duvelisib includes specific, mandatory dose adjustments when co-administered with strong CYP3A4 inhibitors and strong recommendations to avoid co-administration with inducers.[4] This elevates the importance of a meticulous medication reconciliation for any patient considered for duvelisib therapy, as the safe and effective use of the drug is contingent upon managing these potential interactions.

Excretion: Duvelisib has a terminal elimination half-life ranging from 5.2 to 10.9 hours, supporting a twice-daily dosing regimen.[1] The primary route of elimination for the drug and its metabolites is through the feces, which accounts for approximately 79% of an administered dose. A smaller fraction, around 14%, is excreted in the urine.[1] A minor portion of the drug, about 10% of the total dose, is excreted as the unchanged parent compound.[18]

Table 1: Physicochemical and Pharmacokinetic Profile of Duvelisib

Parameter	Value	Source(s)
Identifiers
Brand Name	Copiktra	1
Generic Name	Duvelisib	1
DrugBank ID	DB11952	1
CAS Number	1201438-56-3	1
Chemical Properties
Molecular Formula	C22​H17​ClN6​O (anhydrous)	1
Molecular Weight	416.87 g/mol (anhydrous)	1
IUPAC Name	8-chloro-2-phenyl-3-isoquinolin-1-one	16
Pharmacokinetic Parameters
Bioavailability	42%	18
Time to Peak (Tmax)	1–2 hours	1
Protein Binding	>98%	18
Volume of Distribution	26–102 L	18
Metabolism	Primarily via CYP3A4	18
Elimination Half-life	5.2–10.9 hours	1
Route of Excretion	Feces (79%), Urine (14%)	1

III. Clinical Efficacy in Hematologic Malignancies

The clinical development of duvelisib has focused on its activity in B-cell and T-cell malignancies. Its regulatory approvals were based on two pivotal trials: the Phase 3 DUO study in CLL/SLL and the Phase 2 DYNAMO study in FL. This section provides a critical evaluation of the data from these trials.

A. Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

The cornerstone of duvelisib's approval in CLL/SLL is the DUO trial (NCT02004522), a global, multicenter, randomized, open-label Phase 3 study.[6] The trial was designed to compare the efficacy and safety of oral duvelisib, administered at a dose of 25 mg twice daily, against intravenous ofatumumab monotherapy in a total of 319 patients with R/R CLL/SLL who had received at least one prior therapy.[6]

While the trial enrolled patients with at least one prior therapy, the regulatory approvals from both the FDA and the European Medicines Agency (EMA) were specifically based on a pre-specified subgroup analysis of 196 patients who were more heavily pretreated, having received at least two prior lines of therapy.[8] This decision was based on the assessment that the benefit-to-risk ratio was most favorable in this patient population, which has fewer available treatment options.[29]

Analysis of Primary and Secondary Endpoints

The primary endpoint of the DUO trial was progression-free survival (PFS), as assessed by an Independent Review Committee (IRC). In the regulatory subgroup of 196 patients with two or more prior therapies, duvelisib demonstrated a marked and statistically significant improvement in PFS. The median PFS was 16.4 months for patients in the duvelisib arm, compared to 9.1 months for those in the ofatumumab arm, corresponding to a Hazard Ratio (HR) of 0.40.[8] The benefit was also observed in the overall study population of 319 patients, with a median PFS of 13.3 months for duvelisib versus 9.9 months for ofatumumab (HR=0.52;

p<0.0001).[3]

Secondary endpoints, including overall response rate (ORR), also strongly favored duvelisib. In the heavily pretreated subgroup, the ORR was 78% for patients receiving duvelisib, more than double the 39% ORR observed with ofatumumab.[8] Similar results were seen in the overall population, where the ORR was 73.8% for duvelisib versus 45.3% for ofatumumab (

p<0.0001).[6]

Efficacy in High-Risk Patient Subgroups

Duvelisib's efficacy was maintained in patient subgroups with high-risk cytogenetic features, which are typically associated with poor outcomes. In patients with del(17p) and/or TP53 mutations, a group known to be resistant to conventional chemoimmunotherapy, duvelisib treatment resulted in a median PFS of 12.7 months, compared to 9.0 months with ofatumumab (HR 0.40).[20] This demonstrated that duvelisib provides a meaningful clinical benefit even in the most difficult-to-treat patient populations.

While the results of the DUO trial clearly established the statistical and clinical superiority of duvelisib over its comparator, ofatumumab, the interpretation of this efficacy requires careful contextualization within the modern therapeutic landscape. The DUO trial was initiated in 2014, a time when ofatumumab monotherapy was considered a reasonable standard-of-care comparator for R/R CLL.[6] However, since that time, the treatment paradigm for CLL has been revolutionized by the introduction of highly effective and significantly better-tolerated oral agents, most notably the BTK inhibitors (e.g., ibrutinib, acalabrutinib) and the BCL2 inhibitor venetoclax.[6] These agents now form the backbone of therapy for both frontline and relapsed CLL. Consequently, duvelisib's proven efficacy is relative to a benchmark that is now considered outdated and suboptimal. The DUO trial's design specifically excluded patients who had previously been treated with a BTK or PI3K inhibitor, meaning there is no direct, randomized, comparative data for duvelisib against the current standards of care.[31] This historical context fundamentally defines duvelisib's place in therapy. It is not positioned as a competitor to BTK inhibitors or venetoclax in earlier lines of treatment. Instead, its clinical utility is confined to a later-line setting, primarily for patients whose disease has progressed on, or who are intolerant to, these newer, preferred therapeutic classes.[20] The trial data must be interpreted not just for the positive result it demonstrates, but for the comparative questions it leaves unanswered in the context of the modern therapeutic arsenal.

B. Relapsed/Refractory Follicular Lymphoma (FL)

The evaluation of duvelisib in FL was based on the DYNAMO trial (NCT01882803 / NCT02204982), a single-arm, multicenter Phase 2 study.[9] The trial enrolled patients with indolent non-Hodgkin's lymphoma that was refractory to prior therapies. The cohort that supported the regulatory submission consisted of 83 patients with FL whose disease was "double-refractory," meaning it was refractory to both rituximab and to either chemotherapy or radioimmunotherapy.[8]

Based on the efficacy data from this trial, the FDA granted duvelisib an accelerated approval for this indication in September 2018.[1] This pathway allows for earlier approval of drugs for serious conditions based on a surrogate endpoint, such as ORR, that is considered reasonably likely to predict clinical benefit.

Efficacy Outcomes and Duration of Response

The primary endpoint of the DYNAMO trial was the overall response rate. The IRC assessment determined an ORR of 42% (95% Confidence Interval: 31, 54) in the 83-patient FL cohort.[8] The vast majority of these responses were partial responses, with only one patient achieving a complete response.[9]

The duration of these responses was clinically meaningful, though not exceptionally durable. Among the 35 patients who responded to treatment, 43% (15 patients) maintained their response for at least 6 months, and 17% (6 patients) maintained their response for at least 12 months.[8] These results demonstrated that duvelisib monotherapy had clear anti-tumor activity in a heavily pretreated and difficult-to-treat FL population.

The regulatory journey for the FL indication, however, provides a clear illustration of the intersection between clinical data, regulatory requirements, and commercial strategy. An accelerated approval is conditional; it obligates the sponsor to conduct post-marketing confirmatory trials, typically a randomized Phase 3 study, to verify the predicted clinical benefit on a more definitive endpoint like PFS or overall survival.[13] In December 2021, the sponsor, Secura Bio, announced the voluntary withdrawal of the FL indication in the U.S., which became effective in April 2022.[1] The company's stated rationale was that a strategic business assessment concluded that "the logistics, cost and timing of the post-marketing requirements were no longer merited".[12] This indicates that the decision was not precipitated by new negative data regarding the drug's efficacy or safety in FL. Instead, it was a pragmatic calculation that the potential revenue from the third-line FL market did not justify the substantial financial and operational investment required to conduct a large, randomized confirmatory trial. This is particularly true for a drug with a known challenging safety profile and facing a competitive therapeutic landscape. This event underscores that a drug's availability to patients is not solely dependent on positive clinical data; it is also governed by the complex interplay of regulatory obligations and the commercial viability of meeting those obligations. While the DYNAMO data remains valid in demonstrating duvelisib's activity, the drug is no longer a therapeutic option for this patient population in the United States.

Table 2: Summary of Efficacy Outcomes from the DUO and DYNAMO Trials

Trial Name	Indication	Trial Phase	Design	Patient Population	Primary Endpoint	Key Efficacy Results	Secondary Efficacy Results
DUO (NCT02004522)	R/R CLL/SLL	Phase 3	Randomized vs. Ofatumumab	N=196 (with ≥2 prior therapies)	Progression-Free Survival (PFS)	Median PFS: 16.4 months vs. 9.1 months (HR 0.40)	ORR: 78% vs. 39%
DYNAMO (NCT02204982)	R/R Follicular Lymphoma	Phase 2	Single-Arm	N=83 (double-refractory)	Overall Response Rate (ORR)	ORR: 42% (95% CI: 31, 54)	Duration of Response: 43% of responders maintained response ≥6 months

IV. Comprehensive Safety and Tolerability Profile

The most significant challenge in the clinical use of duvelisib is its substantial and complex toxicity profile. The risks associated with treatment are serious and require vigilant management. This profile led the U.S. FDA to issue a boxed warning, its most severe form of safety alert, which is a central feature of the drug's label and a critical consideration for any prescribing physician.

A. U.S. FDA Boxed Warning: Analysis of Fatal and Serious Toxicities

The boxed warning for duvelisib highlights the risk of four major categories of fatal and/or serious toxicities, all of which are mechanistically linked to the drug's profound effects on the immune system.[1]

Infections

Infections are the most frequent and dangerous complication of duvelisib therapy.

• Incidence: Across clinical trials, fatal and/or serious infections occurred in 31% of patients treated with duvelisib, with 4% of all patients experiencing a fatal infection.[4] The most commonly reported serious infections were pneumonia and sepsis.[4]
• Management: Due to the high risk of opportunistic infections, prophylaxis is a mandatory component of care. Prophylaxis against Pneumocystis jirovecii pneumonia (PJP) is required for all patients during treatment and must be continued after treatment completion until their CD4+ T-cell count recovers to above 200 cells/μL.[4] Prophylactic antiviral therapy to prevent cytomegalovirus (CMV) reactivation should also be strongly considered.[4] If a patient develops signs of a Grade 3 or higher infection, duvelisib must be withheld until the infection is resolved.[4]

Diarrhea and Colitis

Severe gastrointestinal toxicity is another hallmark of duvelisib.

• Incidence: Fatal and/or serious diarrhea or colitis (inflammation of the intestine) occurred in 18% of patients. While fatalities were rare (<1%), the morbidity is significant.[4]
• Management: This is not simple diarrhea and can be an inflammatory, immune-mediated process. Patients should be instructed not to self-medicate with over-the-counter anti-diarrheal agents without first consulting their physician, as this may mask a more serious underlying colitis.[37] Management of moderate to severe cases requires withholding duvelisib and may necessitate treatment with enteric-acting steroids (e.g., budesonide) or systemic corticosteroids to control the inflammation.[36]

Cutaneous Reactions

Severe skin reactions can be life-threatening.

• Incidence: Fatal and/or serious cutaneous reactions were reported in 5% of patients, with fatalities occurring in less than 1% of cases.[4] These reactions can manifest as severe, exfoliative rashes and include rare but life-threatening conditions such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) and Toxic Epidermal Necrolysis (TEN).[4]
• Management: Any severe or life-threatening skin reaction requires immediate and permanent discontinuation of duvelisib.[10]

Pneumonitis

Inflammation of the lungs is a serious and potentially fatal toxicity.

• Incidence: Fatal and/or serious non-infectious pneumonitis occurred in 5% of patients, with a fatality rate of less than 1%.[4]
• Management: Patients presenting with new or worsening pulmonary symptoms such as cough or shortness of breath must be evaluated promptly. Management involves withholding duvelisib, initiating systemic steroid therapy, and potentially discontinuing the drug permanently if the pneumonitis is severe or recurs.[25]

B. Post-Marketing Surveillance: The FDA Safety Communication on Mortality Risk

The initial approval of duvelisib was granted based on a significant benefit in PFS. However, the long-term impact on overall survival (OS) was not mature at the time. As a post-marketing requirement, the FDA mandated the sponsor to provide the final 5-year survival analysis from the DUO trial.[14] The results of this analysis prompted the FDA to issue a formal Drug Safety Communication in June 2022, alerting healthcare professionals and the public to a

possible increased risk of death associated with duvelisib treatment.[14]

The final analysis revealed a concerning trend. The incidence of death from any cause was higher in the duvelisib arm compared to the ofatumumab arm, with a hazard ratio of 1.09.[40] Furthermore, the rates of serious adverse events, dose modifications due to toxicity, and deaths resulting directly from adverse events were all numerically higher in the patients who received duvelisib.[1] These findings led the FDA to convene a meeting of its Oncologic Drugs Advisory Committee (ODAC) to re-evaluate the drug's benefit-risk profile. The committee ultimately voted 8 to 4 that, in light of the new long-term data, the benefits of duvelisib no longer outweighed its risks for its approved indication in CLL/SLL.[41]

This sequence of events provides a powerful illustration of how the benefit-risk assessment of a drug can evolve over time. Initially, the assessment was positive, driven by the clear and statistically significant improvement in PFS, a key measure of disease control.[6] PFS is a widely accepted endpoint for regulatory approval in oncology because it can be measured earlier than overall survival. However, OS, which measures whether a drug helps patients live longer, is considered the gold standard for clinical benefit. The long-term DUO data suggested that any benefit gained from better disease control (improved PFS) may have been offset or even negated by the cumulative or late-onset toxicities of the drug, leading to a lack of an OS benefit and a trend towards harm.[40] This creates a significant clinical and regulatory challenge: a drug that is effective by one important measure but potentially detrimental by the most important measure. This case highlights the critical importance of long-term post-marketing surveillance and demonstrates a broader, class-wide issue for PI3K inhibitors, where a pattern of impressive initial response rates has often been undermined by severe long-term toxicities.[15]

C. Other Clinically Significant Adverse Reactions

Beyond the boxed warnings, duvelisib is associated with several other clinically important adverse reactions that require monitoring and management.

• Hematologic Toxicities: Myelosuppression is very common. Grade 3 or 4 neutropenia (a severe decrease in a type of white blood cell) occurred in 42% of patients receiving duvelisib.[4] Anemia and thrombocytopenia are also frequently reported.[4] Regular monitoring of complete blood counts is essential throughout treatment, with at least weekly checks recommended for patients who develop significant neutropenia.[5]
• Hepatotoxicity: Duvelisib can cause liver injury, manifesting as elevated liver enzymes. Grade 3 or 4 elevations in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) occurred in 8% and 2% of patients, respectively.[5] Liver function tests must be monitored regularly during treatment.[5]
• Common Adverse Events: In addition to the severe toxicities, patients frequently experience a range of other adverse events (reported in ≥20% of patients). These include rash, fatigue, pyrexia (fever), cough, nausea, and musculoskeletal pain.[1] While often less severe, these side effects can significantly impact a patient's quality of life.

D. Management of Adverse Events and Dose Modification Guidelines

The management of duvelisib-related toxicities is protocol-driven and forms a core part of the prescribing information. The general approach for managing Grade 3 or higher non-hematologic toxicities or significant hematologic toxicities involves a three-step process:

1. Withhold Duvelisib: Treatment is temporarily interrupted to allow the patient to recover.
2. Initiate Supportive Care: Specific interventions are started, such as antibiotics for infection, steroids for colitis or pneumonitis, or granulocyte colony-stimulating factor (G-CSF) for neutropenia.
3. Resume at Same or Reduced Dose: Once the adverse event has resolved to Grade 1 or baseline, duvelisib may be resumed, often at a reduced dose level to mitigate the risk of recurrence.[21]

Permanent discontinuation of the drug is required for life-threatening (Grade 4) events, for the recurrence of certain severe (Grade 3) events, or for specific reactions like confirmed PJP or severe cutaneous syndromes (DRESS/TEN).[36]

Table 3: Incidence of Key Adverse Reactions with Duvelisib

Adverse Reaction	All Grades Incidence (%)	Grade ≥3 Incidence (%)	Fatal Incidence (%)
Infections	N/A (Serious infections reported)	31% (Serious)	4%
Diarrhea or Colitis	≥20%	18% (Serious)	<1%
Pneumonitis	N/A (Serious pneumonitis reported)	5% (Serious)	<1%
Cutaneous Reactions	≥20% (Rash)	5% (Serious)	<1%
Neutropenia	≥20%	42%	N/A
ALT/AST Elevation	N/A	8% (ALT), 2% (AST)	N/A
Anemia	≥20%	14%	N/A
Fatigue	≥20%	N/A	N/A
Pyrexia (Fever)	≥20%	N/A	N/A
Cough	≥20%	N/A	N/A
Nausea	≥20%	N/A	N/A
Musculoskeletal Pain	≥20%	N/A	N/A

Note: Data consolidated from prescribing information and clinical trial publications. "Serious" refers to events that are life-threatening, require hospitalization, or result in significant disability. N/A indicates data not specified in this format in the provided sources.[4]

V. Clinical Application and Patient Management

The successful use of duvelisib in the clinic requires a thorough understanding of its administration guidelines, a proactive approach to monitoring and managing its toxicities, and careful consideration of drug-drug interactions and special patient populations.

A. Dosing, Administration, and Therapeutic Monitoring

Recommended Dosage: The standard recommended dose of duvelisib is 25 mg taken orally twice daily.[10] Treatment is continued until there is evidence of disease progression or the development of unacceptable toxicity.[29] The capsules can be taken with or without food but should be swallowed whole and not broken, chewed, or opened.[37]

Dosage Forms: Duvelisib is supplied as 25 mg and 15 mg capsules.[10] The 15 mg strength is specifically intended for use when dose reduction is necessary due to adverse reactions.[42]

Dose Modifications: The management of toxicity is a critical aspect of duvelisib therapy. The first level of dose reduction for a manageable but significant adverse event is to 15 mg twice daily. If a patient is unable to tolerate this reduced dose, duvelisib must be permanently discontinued.[10]

Therapeutic Monitoring: Due to the high incidence of serious adverse events, intensive patient monitoring is mandatory. This includes:

• Blood Counts: Complete blood counts should be monitored at least every two weeks for the first two months of therapy, and at least weekly for any patient whose absolute neutrophil count (ANC) falls below 1.0 Gi/L.[5]
• Liver Function: Liver function tests (ALT, AST, bilirubin) should be monitored regularly throughout treatment to detect hepatotoxicity.[5]
• Clinical Monitoring: Patients must be closely monitored for the signs and symptoms of infection, diarrhea or colitis, new or worsening rash, and pulmonary symptoms such as cough or shortness of breath.[5]

B. Management of Critical Drug-Drug Interactions

As detailed in the pharmacokinetics section, duvelisib's reliance on CYP3A4 for metabolism makes it highly susceptible to drug-drug interactions. Proper management of these interactions is essential for patient safety and treatment efficacy.

• Co-administration with CYP3A4 Inhibitors: Strong inhibitors of CYP3A4 can significantly increase the plasma concentration and exposure (AUC) of duvelisib, thereby increasing the risk of toxicities. When co-administration with a strong CYP3A4 inhibitor is unavoidable, the dose of duvelisib must be reduced to 15 mg twice daily.[4]
• Co-administration with CYP3A4 Inducers: Strong and moderate CYP3A4 inducers can significantly decrease duvelisib exposure, which may compromise its anti-cancer efficacy. Therefore, co-administration with strong or moderate CYP3A4 inducers should be avoided.[4] If co-administration with a moderate inducer is deemed necessary, the prescribing information provides a specific dose escalation schedule for duvelisib to compensate for the reduced exposure.[10]
• Effect on CYP3A4 Substrates: Duvelisib itself is an inhibitor of CYP3A4. This means it can increase the plasma concentrations of other drugs that are sensitive substrates of this enzyme. When duvelisib is co-administered with a sensitive CYP3A4 substrate, particularly one with a narrow therapeutic index, there is an increased risk of toxicity from the co-administered drug. Clinicians should monitor for signs of toxicity and consider reducing the dose of the sensitive CYP3A4 substrate.[4]

C. Use in Specific Populations

The use of duvelisib requires special consideration in certain patient populations.

• Pediatric Population: The safety and effectiveness of duvelisib have not been established in patients under 18 years of age. It is not indicated for use in children.[4]
• Geriatric Population: Clinical studies did not identify specific problems that would limit the usefulness of duvelisib in the elderly compared to younger adults. However, older patients often have more comorbidities and may be more susceptible to the drug's toxicities, warranting careful monitoring.[37]
• Pregnancy and Lactation: Duvelisib can cause harm to a developing fetus. Therefore, it is contraindicated in pregnancy. Pregnancy testing is required for females of reproductive potential before initiating therapy. Both male and female patients must use effective contraception during treatment and for at least one month after the final dose.[4] Due to the potential for serious adverse reactions in a breastfed infant, women should not breastfeed during treatment and for one month after the final dose.[10]
• Impairment of Fertility: Nonclinical studies in animals have shown that duvelisib can impair fertility. Adverse effects were observed in the reproductive organs of both male and female rats, including seminiferous epithelial atrophy, decreased testes weight, decreased ovary weight, and uterine atrophy.[18]

Table 4: Recommended Dose Adjustments for Adverse Reactions and Drug Interactions

Condition	Severity / Type	Recommended Management Action
Part A: Adverse Reactions
Neutropenia	ANC <0.5 Gi/L	Withhold duvelisib. Monitor ANC until >0.5 Gi/L. Resume at same dose (first occurrence) or reduced dose (subsequent occurrences).
Diarrhea / Colitis	Grade 3 (>6 stools/day over baseline) or Colitis with symptoms	Withhold duvelisib. Initiate supportive care (e.g., steroids). Resume at a reduced dose (15 mg BID) upon resolution. Discontinue for recurrence.
Pneumonitis	Grade 2 (symptomatic)	Withhold duvelisib. Treat with systemic steroids. Resume at a reduced dose (15 mg BID) upon resolution.
Pneumonitis	Grade ≥3 (severe/life-threatening)	Discontinue duvelisib permanently.
Cutaneous Reactions	Grade 3	Withhold duvelisib until resolved. Resume at a reduced dose (15 mg BID).
Cutaneous Reactions	Grade 4 (life-threatening) or confirmed DRESS/SJS/TEN	Discontinue duvelisib permanently.
ALT/AST Elevation	>5 to 20 × ULN (Grade 3)	Withhold duvelisib. Monitor until <3 × ULN. Resume at same dose (first occurrence) or reduced dose (subsequent occurrences).
ALT/AST Elevation	>20 × ULN (Grade 4)	Discontinue duvelisib permanently.
Part B: Drug Interactions
Concomitant Medication	Strong CYP3A4 Inhibitor	Reduce duvelisib dose to 15 mg twice daily.
Concomitant Medication	Strong or Moderate CYP3A4 Inducer	Avoid co-administration.

Note: This table is a summary. Clinicians must consult the full prescribing information for complete, detailed management algorithms.[10]

VI. Global Regulatory Trajectory and Market Access

The regulatory history of duvelisib in the United States and Europe has been complex, marked by initial approvals based on clear efficacy data, followed by significant post-marketing scrutiny and strategic adjustments that have shaped its current availability and indications.

A. United States FDA Regulatory History

The journey of duvelisib through the U.S. regulatory process reflects both its therapeutic potential and its significant safety challenges.

• Development and Submission: The New Drug Application (NDA) for duvelisib was submitted by Verastem, Inc. in early 2018. Recognizing the unmet need in the proposed indications, the FDA granted the application Priority Review status, which is reserved for drugs that may offer significant improvements in treatment.[1]
• Initial Approval (September 24, 2018): The FDA granted two approvals for duvelisib on the same day. It received full approval for the treatment of adult patients with R/R CLL or SLL after at least two prior therapies, based on the robust, randomized data from the DUO trial.[1] Concurrently, it received accelerated approval for adult patients with R/R FL after at least two prior systemic therapies, based on the ORR data from the single-arm DYNAMO trial.[1]
• Voluntary Withdrawal of FL Indication (2022): The accelerated approval for FL was contingent upon the completion of a confirmatory trial to verify clinical benefit. In December 2021, the new sponsor, Secura Bio, Inc., announced its intention to voluntarily withdraw this indication. The withdrawal became effective in April 2022.[1] This was a strategic business decision, not a regulatory action prompted by new negative data, based on the company's assessment that the cost and logistics of the required post-marketing study were not commercially justifiable.[12]
• Post-Marketing Safety Re-evaluation (2022): As discussed previously, the final 5-year survival data from the DUO trial raised concerns about a potential increase in the risk of death with duvelisib. This led the FDA to issue a Drug Safety Communication in June 2022 and to convene an advisory committee meeting to re-evaluate the drug's benefit-risk profile.[14] This ongoing scrutiny has further restricted the drug's perceived clinical role.
• Orphan Drug Designations: Throughout its development, duvelisib received several orphan drug designations from the FDA, which are intended to encourage the development of drugs for rare diseases. These included designations for CLL/SLL (2013), FL (2013), and peripheral T-cell lymphoma (PTCL) (2019).[1]

The regulatory story of duvelisib in the United States is not an isolated case but serves as a microcosm of the challenges faced by the entire PI3K inhibitor class in hematologic cancers. The first-in-class PI3K-δ inhibitor, idelalisib, followed a similar trajectory of promising efficacy overshadowed by severe immune-mediated toxicities, resulting in boxed warnings and restricted use.[29] The FDA's 2022 safety communication on duvelisib explicitly stated that the safety findings were similar to those of other drugs in the class.[15] This class-wide concern culminated in a comprehensive FDA advisory committee meeting in April 2022, which reviewed the "totality of evidence" for PI3K inhibitors. The committee's conclusion—that future approvals in this class should be based on randomized trial data rather than single-arm studies due to the difficulty of interpreting safety signals without a comparator arm—has reshaped the regulatory landscape for these agents.[15] Duvelisib's experience is therefore a key chapter in this larger narrative, illustrating a class of drugs with a powerful mechanism but a consistently narrow therapeutic window that demands rigorous regulatory oversight.

B. European Medicines Agency (EMA) Regulatory History

The regulatory process in the European Union followed a different timeline, leading to a slightly different current status for duvelisib.

• Approval Timeline: Following a review of the same DUO and DYNAMO trial data, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for duvelisib on March 25, 2021.[1] This led to the granting of a marketing authorization valid throughout the EU on May 19, 2021.[1]
• Approved Indications: The EMA approved duvelisib for two indications:

1. The treatment of adult patients with R/R CLL after at least two prior therapies.[34]
2. The treatment of adult patients with FL that is refractory to at least two prior systemic therapies.[34]

• Post-Authorisation Monitoring: In the EU, duvelisib is designated as a medicinal product "subject to additional monitoring".[34] This status is applied to new medicines to signal that they are being monitored particularly intensively to gather any new safety information that emerges post-approval. While no specific post-authorization safety studies (PASS) for duvelisib are currently listed by the EMA, the regulatory framework is in place to impose such studies if new safety concerns arise.[34]
• Orphan Drug Designations: Duvelisib also received orphan designations in the EU for the treatment of CLL in 2013 and for PTCL in 2022.[30]

The divergence between the regulatory status of duvelisib in the U.S. and the EU highlights that global drug regulation is not a monolithic process. The EMA's approval still includes the indication for FL, which has been withdrawn in the U.S. This difference stems from several factors. The sponsor's decision to withdraw the U.S. indication was a business decision tied to U.S.-specific post-marketing requirements and did not automatically apply to the European marketing authorization. Furthermore, the EMA's comprehensive review and approval in May 2021 occurred before the final 5-year survival data from the DUO trial and the subsequent FDA safety communication became public in mid-2022. The European label therefore reflects the state of knowledge at the time of its initial approval. The "additional monitoring" status serves as the EMA's mechanism to formally collect and react to new data as it becomes available, including the long-term safety data that has so concerned the FDA. It is plausible that the European position on duvelisib's benefit-risk profile may evolve as this new information is formally assessed.

VII. Synthesis and Future Perspectives

This final section synthesizes the pharmacological, clinical, and regulatory data to provide a conclusive expert opinion on duvelisib's current role in therapy and its potential future directions.

A. Defining the Benefit-Risk Profile of Duvelisib

The clinical value of duvelisib is defined by a sharply delineated benefit-risk profile. The evidence from the DUO trial unequivocally demonstrates that, for patients with heavily pretreated R/R CLL/SLL, duvelisib provides a statistically significant and clinically meaningful improvement in progression-free survival compared to an older standard of care.[6] This ability to control the disease for a median of over a year in a patient population with limited options constitutes a clear therapeutic benefit.

However, this efficacy comes at the cost of a substantial and severe toxicity burden. The risks of fatal and serious infections, diarrhea/colitis, pneumonitis, and cutaneous reactions are not minor concerns; they are frequent, potentially life-threatening complications that require intensive monitoring, mandatory prophylaxis, and expert clinical management.[4] The subsequent emergence of long-term survival data from the DUO trial, which failed to show an overall survival benefit and suggested a possible increased risk of death, further complicates this assessment.[15] This suggests that the toxicities associated with long-term treatment may ultimately outweigh the benefits of disease control.

Therefore, the benefit-risk calculation for duvelisib is highly individualized and dynamic. For a patient with rapidly progressing disease who has exhausted standard therapies, the benefit of achieving disease control may outweigh the immediate risks. However, the balance shifts unfavorably with prolonged exposure, and the decision to use duvelisib must be made with a full understanding of this complex trade-off.

B. Positioning in the Evolving Treatment Paradigm for CLL/SLL

Given its efficacy and safety profile, duvelisib's position in the treatment algorithm for CLL/SLL is clearly defined. It is not a competitor for first- or second-line therapy, where better-tolerated and highly effective agents like BTK inhibitors and venetoclax are the established standards of care.[31]

Duvelisib's role is firmly in the third-line or later setting.[4] Its primary utility is for patients who have progressed after treatment with both a BTK inhibitor and venetoclax. This "double-refractory" population has a significant unmet medical need, and duvelisib, with its distinct mechanism of action, represents a rational therapeutic option.[20] It may also be considered for the rare patient who has contraindications to or is intolerant of both BTK inhibitors (e.g., due to severe cardiovascular conditions) and venetoclax (e.g., due to a very high risk of tumor lysis syndrome, which is not a major concern with duvelisib).[20]

C. Ongoing and Future Research: Peripheral T-Cell Lymphoma and Combination Strategies

While its role in B-cell malignancies is limited, the future of duvelisib may be redefined by ongoing research in other areas, particularly T-cell lymphomas.

• Peripheral T-Cell Lymphoma (PTCL): PTCL is a heterogeneous group of aggressive non-Hodgkin lymphomas with generally poor outcomes and a high unmet need for effective therapies.[27] Duvelisib's dual inhibition of PI3K- δ and PI3K-γ is mechanistically relevant for these diseases, as these pathways are implicated in T-cell signaling and the tumor microenvironment. The drug has received Orphan Drug and Fast Track designations for PTCL from regulatory agencies, and clinical trials are actively exploring its use both as a monotherapy and in combination with other agents like the HDAC inhibitor romidepsin and the proteasome inhibitor bortezomib.[1]

The active development of duvelisib in PTCL represents a clear strategic pivot by the sponsor. The clinical and commercial landscape for B-cell malignancies like CLL is intensely competitive and dominated by agents with more favorable safety profiles. In contrast, PTCL remains an area with few effective treatments. A successful clinical program in PTCL could provide a "second act" for duvelisib, establishing a new niche where its potent mechanism may offer a more favorable benefit-risk balance. This strategic shift is a direct response to the challenges the drug has faced in its initial indications and represents a calculated effort to align its unique mechanism with a population of high unmet medical need.

• Combination Strategies: Beyond PTCL, early-phase studies have explored combining duvelisib with standard immunochemotherapy agents like rituximab and bendamustine, though the future of such combinations will depend on managing cumulative toxicities.[53]

D. Concluding Remarks and Expert Recommendations

Duvelisib is an effective oral agent for controlling disease in heavily pretreated patients with relapsed or refractory CLL/SLL. However, its potent dual PI3K-δ/γ inhibitory mechanism is intrinsically linked to a profile of severe and potentially fatal immune-mediated toxicities.

Based on the totality of the available evidence, the following recommendations are made:

1. Restrict Use: The use of duvelisib should be strictly limited to its approved indication: adult patients with R/R CLL/SLL who have received at least two prior lines of therapy, including a BTK inhibitor and venetoclax, or for whom these standard therapies are not appropriate.
2. Expert Management: Duvelisib should only be prescribed by hematologist-oncologists with expertise in managing its complex toxicity profile. Treatment requires a commitment to intensive patient monitoring, mandatory PJP prophylaxis, and rapid intervention for adverse events.
3. Informed Patient Consent: The decision to initiate therapy must be preceded by a thorough and transparent discussion with the patient. This conversation must clearly articulate the significant potential risks, including the boxed warnings for fatal complications and the uncertain impact on overall survival.
4. Monitor Future Research: The results of ongoing clinical trials in PTCL are of high interest and have the potential to redefine the primary clinical role of duvelisib. These data should be monitored closely as they emerge.

In its current role, duvelisib remains a valuable tool for a small, well-defined patient population with few remaining options. However, its use demands the utmost caution, vigilance, and clinical expertise to navigate the narrow therapeutic window between efficacy and toxicity.

Works cited

1. Duvelisib - Wikipedia, accessed August 19, 2025, https://en.wikipedia.org/wiki/Duvelisib
2. What type of drug is Copiktra? - Drugs.com, accessed August 19, 2025, https://www.drugs.com/medical-answers/type-drug-copiktra-3445567/
3. Verastem Submits New Drug Application to U.S. FDA for Duvelisib for the Treatment of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma | Verastem, Inc., accessed August 19, 2025, https://investor.verastem.com/news-releases/news-release-details/verastem-submits-new-drug-application-us-fda-duvelisib-treatment/
4. COPIKTRA® (duvelisib) Capsules for Relapsed CLL/SLL, accessed August 19, 2025, https://copiktra.com/
5. CLL/SLL (chronic lymphocytic leukemia/small lymphocytic lymphoma) Treatment - COPIKTRA® (duvelisib) - HCP Site, accessed August 19, 2025, https://copiktrahcp.com/cll-sll/
6. The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL | Blood, accessed August 19, 2025, https://ashpublications.org/blood/article/132/23/2446/40003/The-phase-3-DUO-trial-duvelisib-vs-ofatumumab-in
7. The phase III DUO trial of PI3K inhibitor duvelisib versus ofatumumab in relapsed/refractory chronic lymphocytic leukemia/small - Haematologica, accessed August 19, 2025, https://haematologica.org/article/view/haematol.2024.285043/77109
8. Duvelisib Approved for Patients with CLL or SLL | ASH Clinical News, accessed August 19, 2025, https://ashpublications.org/ashclinicalnews/news/4124/Duvelisib-Approved-for-Patients-with-CLL-or-SLL
9. duvelisib (COPIKTRA, Verastem, Inc.) for adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) | FDA, accessed August 19, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/duvelisib-copiktra-verastem-inc-adult-patients-relapsed-or-refractory-chronic-lymphocytic-leukemia
10. www.accessdata.fda.gov, accessed August 19, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211155s007lbl.pdf
11. U.S. Food and Drug Administration Approves Duvelisib (COPIKTRA) for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Follicular Lymphoma - Lymphoma Research Foundation, accessed August 19, 2025, https://lymphoma.org/news/u-s-food-and-drug-administration-approves-duvelisib-copiktra-for-relapsedrefractory-chronic-lymphocytic-leukemiasmall-lymphocytic-lymphoma-and-follicular-lymphoma/
12. Copiktra (duvelisib) FDA Approval History - Drugs.com, accessed August 19, 2025, https://www.drugs.com/history/copiktra.html
13. Secura Bio, Inc.; Withdrawal of Approval of Relapsed or Refractory Follicular Lymphoma Indication for COPIKTRA - Federal Register, accessed August 19, 2025, https://www.federalregister.gov/documents/2022/04/13/2022-07931/secura-bio-inc-withdrawal-of-approval-of-relapsed-or-refractory-follicular-lymphoma-indication-for
14. Copiktra (duvelisib): Drug Safety Communication - FDA Warns about Possible Increased Risk of Death and Serious Side Effects, accessed August 19, 2025, https://www.fda.gov/safety/medical-product-safety-information/copiktra-duvelisib-drug-safety-communication-fda-warns-about-possible-increased-risk-death-and
15. FDA warns about possible increased risk of death and serious side effects with cancer drug Copiktra (duvelisib), accessed August 19, 2025, https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-about-possible-increased-risk-death-and-serious-side-effects-cancer-drug-copiktra
16. Duvelisib | C22H17ClN6O | CID 50905713 - PubChem, accessed August 19, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Duvelisib
17. Safety Data Sheet Duvelisib Page 1 of 4 Section 1: Identification, accessed August 19, 2025, https://tribioscience.com/wp-content/uploads/2023/09/TBI4788_Duvelisib_MSDS_2024.pdf
18. Duvelisib: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 19, 2025, https://go.drugbank.com/drugs/DB11952
19. Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies | Blood, accessed August 19, 2025, https://ashpublications.org/blood/article/131/8/877/104433/Duvelisib-a-novel-oral-dual-inhibitor-of-PI3K-is
20. Duvelisib (Copiktra) in relapsed or refractory chronic lymphocytic leukemia: safety and efficacy - PubMed, accessed August 19, 2025, https://pubmed.ncbi.nlm.nih.gov/33499685/
21. Copiktra (Duvelisi Capsules): Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed August 19, 2025, https://www.rxlist.com/copiktra-drug.htm
22. CAS 1201438-56-3 Duvelisib - BOC Sciences, accessed August 19, 2025, https://www.bocsci.com/duvelisib-cas-1201438-56-3-item-462545.html
23. IPI 145 | 1201438-56-3 - ChemicalBook, accessed August 19, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB32645143.htm
24. Duvelisib (IPI-145, INK1197) - PI3K - APExBIO, accessed August 19, 2025, https://www.apexbt.com/duvelisib-ipi-145-ink1197.html
25. Duvelisib: MedlinePlus Drug Information, accessed August 19, 2025, https://medlineplus.gov/druginfo/meds/a618056.html
26. duvelisib oral: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD, accessed August 19, 2025, https://www.webmd.com/drugs/2/drug-176153/duvelisib-oral/details
27. Duvelisib: A Phosphoinositide-3 Kinase δ/γ Inhibitor for Chronic Lymphocytic Leukemia, accessed August 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5584596/
28. Definition of duvelisib - NCI Drug Dictionary, accessed August 19, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/duvelisib
29. Copiktra (Duvelisib) Approved for Relapsed or Refractory CLL, SLL, and Follicular Lymphoma, accessed August 19, 2025, https://jhoponline.com/2019-fourth-annual-oncology-guide-to-new-fda-approvals/copiktra-duvelisib-approved-for-relapsed-or-refractory-cll-sll-and-follicular-lymphoma
30. Duvelisib for Relapsed or Refractory Chronic Lymphocytic Leukaemia - NIHR Innovation Observatory, accessed August 19, 2025, https://www.io.nihr.ac.uk/wp-content/uploads/2022/01/31246-Duvelisib-for-Relapsed-or-Refractory-Chronic-Lymphocytic-Leukaemia-V1.0-JUN2021-NON_CONF.pdf
31. Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma - PMC, accessed August 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9635582/
32. Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases - PMC, accessed August 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6631818/
33. Duvelisib Capsules: Uses & Side Effects - Cleveland Clinic, accessed August 19, 2025, https://my.clevelandclinic.org/health/drugs/21255-duvelisib-capsules
34. Copiktra | European Medicines Agency (EMA), accessed August 19, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/copiktra
35. Duvelisib (Copiktra®) for the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia, accessed August 19, 2025, https://eprints.aihta.at/1304/1/Oncology%20Fact%20Sheet%20Nr.44_Update.pdf
36. Copiktra (duvelisib) dosing, indications, interactions, adverse effects, and more, accessed August 19, 2025, https://reference.medscape.com/drug/copiktra-duvelisib-1000261
37. Duvelisib (oral route) - Side effects & dosage - Mayo Clinic, accessed August 19, 2025, https://www.mayoclinic.org/drugs-supplements/duvelisib-oral-route/description/drg-20444077
38. Copiktra - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed August 19, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/211155s000lbl.pdf
39. Copiktra, INN-duvelisib - European Medicines Agency, accessed August 19, 2025, https://www.ema.europa.eu/en/documents/product-information/copiktra-epar-product-information_en.pdf
40. Duvelisib: uses, dosing, warnings, adverse events, interactions, accessed August 19, 2025, https://www.oncologynewscentral.com/drugs/monograph/176153-318052/duvelisib-oral
41. Secura's Copiktra: Trial Design, Shifting Standard Of Care Could Spell The End For Third-Line CLL/SLL - Citeline News & Insights, accessed August 19, 2025, https://insights.citeline.com/PS147039/Securas-Copiktra-Trial-Design-Shifting-Standard-Of-Care-Could-Spell-The-End-For-ThirdLine-CLLSLL/
42. This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed August 19, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211155s001lbl.pdf
43. FDA Accepts New Drug Application for Duvelisib and Grants Priority Review | Verastem, Inc., accessed August 19, 2025, https://investor.verastem.com/news-releases/news-release-details/fda-accepts-new-drug-application-duvelisib-and-grants-priority/
44. Duvelisib: A 2018 Novel FDA-Approved Small Molecule Inhibiting Phosphoinositide 3-Kinases - MDPI, accessed August 19, 2025, https://www.mdpi.com/1424-8247/12/2/69
45. Duvelisib receives a positive opinion from the EMA CHMP for the treatment of R/R CLL and refractory FL - Lymphoma Hub, accessed August 19, 2025, https://lymphomahub.com/medical-information/duvelisib-receives-a-positive-opinion-from-the-ema-chmp-for-the-treatment-of-rr-cll-and-refractory-fl
46. EMA grants marketing authorization to duvelisib monotherapy for R/R CLL or FL, accessed August 19, 2025, https://lymphomahub.com/medical-information/ema-grants-marketing-authorization-to-duvelisib-monotherapy-for-rr-cll-or-fl
47. Drugs@EMA: Drug Product Copiktra (duvelisib), Secura Bio Limited - PharmGKB, accessed August 19, 2025, https://www.clinpgx.org/literature/15135902
48. Post-authorisation safety studies (PASS) | European Medicines Agency (EMA), accessed August 19, 2025, https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/pharmacovigilance-post-authorisation/post-authorisation-safety-studies-pass
49. Lessons learned on the design and the conduct of Post‐Authorization Safety Studies: review of 3 years of PRAC oversight - PubMed Central, accessed August 19, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5346857/
50. EU/3/22/2730 - orphan designation for treatment of peripheral T-cell lymphoma - EMA, accessed August 19, 2025, https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-22-2730
51. Duvelisib Plus Romidepsin Yields High Results in Relapsed/Refractory Peripheral T-Cell Lymphoma - CancerNetwork, accessed August 19, 2025, https://www.cancernetwork.com/view/duvelisib-plus-romidepsin-yields-high-results-in-relapsed-refractory-peripheral-t-cell-lymphoma
52. A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) (PRIMO) - ClinicalTrials.gov, accessed August 19, 2025, https://www.clinicaltrials.gov/ct2/show/NCT03372057?term=NCT03372057&rank=1
53. Duvelisib Completed Phase 1 Trials for Lymphoma / Chronic Lymphocytic Leukemia / T-Cell Lymphoma / Non-Hodgkin's Lymphoma (NHL) Treatment - DrugBank, accessed August 19, 2025, https://go.drugbank.com/drugs/DB11952/clinical_trials?conditions=DBCOND0028332%2CDBCOND0006647%2CDBCOND0030854%2CDBCOND0032037&phase=1&purpose=treatment&status=completed